Working across clinical and non-clinical areas, in close partnership with the NHS, industry, and other stakeholders, including our patient populations, we aim to develop medicines more efficiently, embed advanced treatments into routine clinical care, and develop policies that direct treatment for the most impact on human health and animal welfare.
Key aims
Better therapeutics (making medicines better)
The drug discovery pipeline is complex. Late-stage failures often cost the pharmaceutical industry billions. Failures also often mean that commercial interest wanes, leaving clinical need unmet. One reason is that animal models do not readily translate into human targets and disease. Ideally target discovery should be in humans, with experimental studies supporting mechanisms. To overcome this bottleneck, we've developed and are delivering scalable mechanisms for drug target discovery, aligning with a cross-Faculty University Research Frontier in Therapeutics innovation.
Better targeting (using medicines better)
We're enhancing the use of existing therapeutics and building on our expertise in drug safety, understanding the mechanisms of drug toxicity and extending beyond liver toxicity and immunotoxicity. Already home to a unique resource for clinicians to reduce drug-drug interactions, we're expanding the ability to more safely use medicines through a pharmacogenomics approach.
Enhanced clinical relevance
Our programme of making and using medicines better will have direct clinical impact in the short and longer term, regionally, nationally and internationally. We're directing our efforts into clinical translation through clinical trials. We focus on unmet need and improving the health of people within the Liverpool City Region, demonstrating how this can be effectively implemented into policy, but also into a global vision.
.jpg)
